Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer
R C Coombes, P D Badman, J P Lozano-Kuehne, X Liu, I R Macpherson, I Zubairi, R D Baird, N Rosenfeld, J Garcia-Corbacho, N Cresti, R Plummer, A Armstrong, R Allerton, D Landers, H Nicholas, L McLellan, A Lim, F Mouliere, O E Pardo, V Ferguson, M J Seckl, R C Coombes, P D Badman, J P Lozano-Kuehne, X Liu, I R Macpherson, I Zubairi, R D Baird, N Rosenfeld, J Garcia-Corbacho, N Cresti, R Plummer, A Armstrong, R Allerton, D Landers, H Nicholas, L McLellan, A Lim, F Mouliere, O E Pardo, V Ferguson, M J Seckl
Abstract
We conducted a phase IIa, multi-centre, open label, single arm study (RADICAL; NCT01791985) of AZD4547 (a potent and selective inhibitor of Fibroblast Growth Factor Receptor (FGFR)-1, 2 and 3 receptor tyrosine kinases) administered with anastrozole or letrozole in estrogen receptor positive metastatic breast cancer patients who had become resistant to aromatase inhibitors. After a safety run-in study to assess safety and tolerability, we recruited 52 patients. The primary endpoint was change in tumour size at 12 weeks, and secondary endpoints were to assess response at 6 weeks, 20 weeks and every 8 weeks thereafter and tolerability of the combined treatment. Two partial responses (PR) and 19 stable disease (SD) patients were observed at the 12-week time point. At 28 weeks, according to centrally reviewed Response Evaluation Criteria in Solid Tumours (RECIST) criteria, five PR and 8 SD patients were observed in 50 assessable cases. Overall, objective response rate (5 PR) was of 10%, meeting the pre-specified endpoint. Fourteen patients discontinued due to adverse events. Eleven patients had retinal pigment epithelial detachments which was asymptomatic and reversible in all but one patient. Exploratory ribonucleic acid sequencing (RNA-Seq) analysis was done on patients' samples: 6 differentially-expressed-genes could distinguish those who benefited from the addition of AZD4547.
Conflict of interest statement
N.R. is co-founder and officer of Inivata, a company that commercialises technologies for ctDNA analysis. D.L. consults to Astrazeneca (AZ) and was an employee in the past. His research team has also received grant funding from AZ. He also has a Director role and is an employee of his own consultancy company DeLondra Oncology Ltd. RCC currently has a grant from AZ. I.M. consults to AZ. R.B. consults to AZ and has received grant funding, travel, accommodation, expenses from AZ. A.A. has received grant funding to her Institution from AZ. P.B., I.Z., X.L., J.P.L.K., H.N., M.S., N.C., E.P., L.M., A.L., F.M., O.P., R.A., J.G.C. and V.F. have indicated no competing interests.
© 2022. The Author(s).
Figures
References
- Ferlay J, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J. Cancer. 2015;136:E359–E386. doi: 10.1002/ijc.29210.
- Santa-Maria CA, et al. Changing treatment paradigms metastatic breast cancer: lessons learned. JAMA Oncol. 2015;549:528–534. doi: 10.1001/jamaoncol.2015.1198.
- Ma, X. et al. Mechanisms of aromatase inhibitor resistance. Nat. Rev. Cancer15, 261–275 (2015).
- Luqmani YA, et al. Expression of 2 variant forms of fibroblast growth factor receptor 1 in human breast. Int J. Cancer. 1995;64:274–279. doi: 10.1002/ijc.2910640411.
- Turner N, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 2010;70:2085–2094. doi: 10.1158/0008-5472.CAN-09-3746.
- Saka H, et al. Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a phase I study. Invest New Drugs. 2017;35:451–462. doi: 10.1007/s10637-016-0416-x.
- Andre, F. et al. Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumours. Cancer Res.73, abst LB-145 (2013).
- Mouliere F, et al. Enhanced detection of circulating tumor DNA with fragment size analysis. Sci. Transl. Med. 2018;10:eaat4921. doi: 10.1126/scitranslmed.aat4921.
- Van Cutsem E, et al. A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification. Ann. Oncol. 2017;28:1316–1324. doi: 10.1093/annonc/mdx107.
- Paik PK, et al. A phase 1b open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers: preliminary antitumor activity and pharmacodynamic data. ASCO Annu. Meet. J. Clin. Oncol. 2014;32:5s.
- Hui R, et al. Lucitanib for the treatment of HR+/HER2− metastatic breast cancer: results from the multicohort phase II FINESSE Study. Clin. Cancer Res. 2020;26:354–363. doi: 10.1158/1078-0432.CCR-19-1164.
- Schuler M, et al. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2019;20:1454–1466. doi: 10.1016/S1470-2045(19)30412-7.
- Musolino A, et al. Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2− breast cancer that had progressed during or after prior endocrine therapy. Breast Cancer Res. 2017;19:18. doi: 10.1186/s13058-017-0807-8.
- Loriot Y, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N. Engl. J. Med. 2019;381:338–348. doi: 10.1056/NEJMoa1817323.
- Servetto A, et al. FGFR signalling and endocrine resistance in breast cancer: challenges for the development of FGFR inhibitors. Biochim Biophys. Acta Rev. Cancer. 2021;1876:188595–188598. doi: 10.1016/j.bbcan.2021.188595.
- Mao P, et al. Acquired FGFR and FGF alterations confer resistance to ER targeted therapy in ER+ metastatic breast cancer. Clin. Cancer Res. 2020;26:5974–5989. doi: 10.1158/1078-0432.CCR-19-3958.
- Formisano L, et al. Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. Nat. Commun. 2019;10:1373. doi: 10.1038/s41467-019-09068-2.
- Eisenhauer EA, et al. New response evaluation criteria in solid tumours: revised RECIST guideline. Eur. J. Cancer. 2009;45:228–247. doi: 10.1016/j.ejca.2008.10.026.
- Van der Pol, Y. et al. Towards the early detection of cancer by decoding the epigenetic and micro-environmental fingerprints of cell-free DNA. Cancer Cell.10.1016/j.ccell.2019.09.003 (2019).
Source: PubMed